NCR+ ILC3s tend to be anti-tumoral, producing IL-22 and TNF in contexts such as early-stage lung cancer and mucosal immunity, whereas NCR- ILC3s typically produce IL-17 and support tumor growth in CRC, liver, and pancreatic cancers (186, 194). This evidence concerns the gene IL17A and neoplasm.